Breaking News, Collaborations & Alliances

Bionomics, Merck in Pain Pact

Will focus on discovery of new pain treatments

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bionomics Ltd. has entered a two-year agreement with Merck to discover and develop small molecule candidates for the treatment of chronic pain, including neuropathic pain. Bionomics will use its ionX drug discovery platform and MultiCore chemistry to identify potential drug candidates.   Merck will have the option to exclusively license a compound from Bionomics for further development and Bionomics may receive option fees and development and regulatory milestone payments of as much as $172 mill...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters